Published in Biochem Pharmacol on May 06, 2016
Evaluation of Lumazine Synthase from Bacillus anthracis as a Presentation Platform for Polyvalent Antigen Display. Protein Sci (2017) 0.75
Immunization with Recombinant TcdB-Encapsulated Nanocomplex Induces Protection against Clostridium difficile Challenge in a Mouse Model. Front Microbiol (2017) 0.75
The serial cultivation of human diploid cell strains. Exp Cell Res (1961) 25.11
Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med (1980) 9.34
TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol (2008) 7.87
Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol (1965) 7.58
An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci U S A (1968) 7.33
Cultivation of the Lansing Strain of Poliomyelitis Virus in Cultures of Various Human Embryonic Tissues. Science (1949) 7.29
Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol (2001) 6.62
Fabrication of novel biomaterials through molecular self-assembly. Nat Biotechnol (2003) 6.57
A "NEW" ANTIGEN IN LEUKEMIA SERA. JAMA (1965) 6.21
Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. J Am Med Assoc (1953) 5.66
Coiled coils: a highly versatile protein folding motif. Trends Cell Biol (2001) 5.55
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science (2007) 4.90
PLGA-based nanoparticles: an overview of biomedical applications. J Control Release (2012) 4.39
A TEN YEAR OLD STRAIN OF FIBROBLASTS. J Exp Med (1922) 4.37
Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin. Nat Immunol (2008) 4.08
Structure of the bacterial flagellar protofilament and implications for a switch for supercoiling. Nature (2001) 3.92
Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature (1982) 3.82
Synthesis of hepatitis B surface and core antigens in E. coli. Nature (1981) 3.11
Solving the structure of human H ferritin by genetically engineering intermolecular crystal contacts. Nature (1991) 3.10
Expression in Escherichia coli of hepatitis B virus DNA sequences cloned in plasmid pBR322. Nature (1979) 3.03
The crystal structure of Dps, a ferritin homolog that binds and protects DNA. Nat Struct Biol (1998) 3.02
Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano (2008) 2.76
Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci U S A (2004) 2.74
The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol (2003) 2.73
More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov (2007) 2.68
Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol (2010) 2.68
Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis (1985) 2.64
Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis (1992) 2.55
Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am J Public Health Nations Health (1954) 2.39
Liposomes as immunological adjuvants. Nature (1974) 2.37
Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn (2009) 2.35
Studies on variants of poliomyelitis virus. I. Experimental segregation and properties of avirulent variants of three immunologic types. J Exp Med (1954) 2.33
Direct and indirect effects of single walled carbon nanotubes on RAW 264.7 macrophages: role of iron. Toxicol Lett (2006) 2.30
Sepsis: current dogma and new perspectives. Immunity (2014) 2.22
Molecular engineering: An approach to the development of general capabilities for molecular manipulation. Proc Natl Acad Sci U S A (1981) 2.20
CpG DNA as a vaccine adjuvant. Expert Rev Vaccines (2011) 2.17
Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ (2008) 2.16
Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J Immunol (2004) 2.13
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature (2013) 2.08
Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol (1986) 1.98
Virus-like particles: passport to immune recognition. Methods (2006) 1.89
"Herd immunity": a rough guide. Clin Infect Dis (2011) 1.85
Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev (2009) 1.83
Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines (2007) 1.79
Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine (2006) 1.74
Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med (2015) 1.74
A self-assembling peptide acting as an immune adjuvant. Proc Natl Acad Sci U S A (2009) 1.62
Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis. Expert Rev Vaccines (2012) 1.62
Paralytic poliomyelitis: Old dogmas and new perspectives. Rev Infect Dis (1981) 1.62
Long, needle-like carbon nanotubes and asbestos activate the NLRP3 inflammasome through a similar mechanism. ACS Nano (2011) 1.62
Mucosal administration of flagellin induces innate immunity in the mouse lung. Infect Immun (2004) 1.56
TLR9 as a key receptor for the recognition of DNA. Adv Drug Deliv Rev (2008) 1.52
Antigen-containing liposomes engrafted with flagellin-related peptides are effective vaccines that can induce potent antitumor immunity and immunotherapeutic effect. J Immunol (2010) 1.51
Nanoparticle vaccines. Vaccine (2013) 1.51
A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J Immunol (2009) 1.50
Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine (2012) 1.49
Identification of conserved domains in Salmonella muenchen flagellin that are essential for its ability to activate TLR5 and to induce an inflammatory response in vitro. J Biol Chem (2003) 1.46
Salmonella flagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the protein. J Immunol (2001) 1.46
Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees. Am J Med Sci (1977) 1.43
Formation and structure of a NAIP5-NLRC4 inflammasome induced by direct interactions with conserved N- and C-terminal regions of flagellin. J Biol Chem (2012) 1.41
Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. Cell Mol Life Sci (2009) 1.39
Responses to the soluble flagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur J Immunol (2004) 1.38
Two nonadjacent regions in enteroaggregative Escherichia coli flagellin are required for activation of toll-like receptor 5. J Biol Chem (2002) 1.37
Cellular and humoral immunity in guinea pigs to two major polypeptides derived from hepatitis B surface antigen. J Gen Virol (1978) 1.37
Peptide and protein building blocks for synthetic biology: from programming biomolecules to self-organized biomolecular systems. ACS Chem Biol (2008) 1.36
Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine. PLoS One (2012) 1.35
Clinical evaluation of a recombinant hepatitis B vaccine. Lancet (1984) 1.33
The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine (2012) 1.33
Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. Nanomedicine (2006) 1.32
Co-assembling peptides as defined matrices for endothelial cells. Biomaterials (2009) 1.32
Immunisation against hepatitis B in man. Lancet (1976) 1.31
Natural History and Clinical Consequences of Hepatitis B Virus Infection. Int J Med Sci (2005) 1.30
Viral hepatitis, type B (MS-2 strain). Studies on active immunization. JAMA (1971) 1.29
The use of Toll-like receptor 7/8 agonists as vaccine adjuvants. Expert Rev Vaccines (2013) 1.26
Purified and inactivated human hepatitis B vaccine: progress report. Am J Med Sci (1977) 1.22
Modern subunit vaccines: development, components, and research opportunities. ChemMedChem (2013) 1.22
Enzymatic modification of self-assembled peptide structures with tissue transglutaminase. Bioconjug Chem (2003) 1.21
Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol (2011) 1.20
The development of vaccines: how the past led to the future. Nat Rev Microbiol (2011) 1.19
Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem Biol Drug Des (2009) 1.18
The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology (2007) 1.18
Coiled coils: attractive protein folding motifs for the fabrication of self-assembled, responsive and bioactive materials. Chem Soc Rev (2010) 1.17
Production of immunologically active surface antigens of hepatitis B virus by Escherichia coli. Proc Natl Acad Sci U S A (1981) 1.16
The Spatial Dynamics of Poliomyelitis in the United States: From Epidemic Emergence to Vaccine-Induced Retreat, 1910-1971. Ann Assoc Am Geogr (2005) 1.16
Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect (1986) 1.13
Flagellin enhances NK cell proliferation and activation directly and through dendritic cell-NK cell interactions. J Leukoc Biol (2005) 1.12
TLR8: the forgotten relative revindicated. Cell Mol Immunol (2012) 1.12
The immunobiology of toll-like receptor 4 agonists: from endotoxin tolerance to immunoadjuvants. Shock (2013) 1.12
Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods (2006) 1.11
Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo. ACS Nano (2013) 1.10
Measles elimination in the United States. J Infect Dis (2004) 1.09
Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016. MMWR Morb Mortal Wkly Rep (2015) 1.08
An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines (2013) 1.08
Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine (2014) 1.07
Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine (1998) 1.07
A vault nanoparticle vaccine induces protective mucosal immunity. PLoS One (2009) 1.07
The virosome concept for influenza vaccines. Vaccine (2005) 1.07
Vaccination and herd immunity: what more do we know? Curr Opin Infect Dis (2012) 1.07
The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine (1999) 1.06
Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine. Chem Biol Drug Des (2012) 1.06